Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Simone Koole; Ruby van Stein; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group; Karolina Sikorska; Desmond Barton; Lewis Perrin; Donal Brennan; Oliver Zivanovic; Berit Jul Mosgaard; Anna Fagotti; Pierre-Emmanuel Colombo; Gabe Sonke; W J van Driel

doi:10.1136/ijgc-2020-001231

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Simone Koole, Ruby van Stein, OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group, Karolina Sikorska, Desmond Barton, Lewis Perrin, Donal Brennan, Oliver Zivanovic, Berit Jul Mosgaard, Anna Fagotti, Pierre-Emmanuel Colombo, Gabe Sonke, W J van Driel^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

83 Citations (Scopus)

Abstract

BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.

PRIMARY OBJECTIVE: The primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease, or residual disease up to 2.5 mm in maximum dimension.

STUDY HYPOTHESIS: We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with primary FIGO stage III epithelial ovarian cancer.

TRIAL DESIGN: This international, randomized, open-label, phase III trial will enroll 538 patients with newly diagnosed FIGO stage III epithelial ovarian cancer. Following complete or near-complete (residual disease ≤2.5 mm) primary cytoreduction, patients are randomly allocated (1:1) to receive HIPEC or no HIPEC. All patients will receive six courses of platinum-paclitaxel chemotherapy, and maintenance PARP-inhibitor or bevacizumab according to current guidelines.

MAJOR ELIGIBILITY CRITERIA: Patients with FIGO stage III primary epithelial ovarian, fallopian tube, or primary peritoneal cancer are eligible after complete or near-complete primary cytoreductive surgery. Patients with resectable umbilical, spleen, or local bowel lesions may be included. Enlarged extra-abdominal lymph nodes should be negative on FDG-PET or fine-needle aspiration/biopsy.

PRIMARY ENDPOINT: The primary endpoint is overall survival.

SAMPLE SIZE: To detect a HR of 0.67 in favor of HIPEC, 200 overall survival events are required. With an expected accrual period of 60 months and 12 months additional follow-up, 538 patients need to be randomized.

ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The OVHIPEC-2 trial started in January 2020 and primary analyses are anticipated in 2026.

TRIAL REGISTRATION: ClinicalTrials.gov:NCT03772028.

Original language	English
Pages (from-to)	888-892
Number of pages	5
Journal	International Journal of Gynecological Cancer
Volume	30
Issue number	6
DOIs	https://doi.org/10.1136/ijgc-2020-001231
Publication status	Published - 1 Jun 2020
Externally published	Yes

Bibliographical note

Funding:
The trial is funded by the Dutch Cancer Society (DCS), the Netherlands
Organization for Health Research and Development (ZonMW), and the Coverage
with Evidence Development (CED) program of the Dutch Ministry of Health.

© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/ijgc-2020-001231

Cite this

Koole, S., van Stein, R., OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group, Sikorska, K., Barton, D., Perrin, L., Brennan, D., Zivanovic, O., Mosgaard, B. J., Fagotti, A., Colombo, P.-E., Sonke, G., & Driel, W. J. V. (2020). Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. International Journal of Gynecological Cancer, 30(6), 888-892. https://doi.org/10.1136/ijgc-2020-001231

Koole, Simone ; van Stein, Ruby ; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group et al. / Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer : OVHIPEC-2, a phase III randomized clinical trial. In: International Journal of Gynecological Cancer. 2020 ; Vol. 30, No. 6. pp. 888-892.

@article{3b390e90db0f44baae157b6fb90aa3f2,

title = "Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial",

abstract = "BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.PRIMARY OBJECTIVE: The primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease, or residual disease up to 2.5 mm in maximum dimension.STUDY HYPOTHESIS: We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with primary FIGO stage III epithelial ovarian cancer.TRIAL DESIGN: This international, randomized, open-label, phase III trial will enroll 538 patients with newly diagnosed FIGO stage III epithelial ovarian cancer. Following complete or near-complete (residual disease ≤2.5 mm) primary cytoreduction, patients are randomly allocated (1:1) to receive HIPEC or no HIPEC. All patients will receive six courses of platinum-paclitaxel chemotherapy, and maintenance PARP-inhibitor or bevacizumab according to current guidelines.MAJOR ELIGIBILITY CRITERIA: Patients with FIGO stage III primary epithelial ovarian, fallopian tube, or primary peritoneal cancer are eligible after complete or near-complete primary cytoreductive surgery. Patients with resectable umbilical, spleen, or local bowel lesions may be included. Enlarged extra-abdominal lymph nodes should be negative on FDG-PET or fine-needle aspiration/biopsy.PRIMARY ENDPOINT: The primary endpoint is overall survival.SAMPLE SIZE: To detect a HR of 0.67 in favor of HIPEC, 200 overall survival events are required. With an expected accrual period of 60 months and 12 months additional follow-up, 538 patients need to be randomized.ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The OVHIPEC-2 trial started in January 2020 and primary analyses are anticipated in 2026.TRIAL REGISTRATION: ClinicalTrials.gov:NCT03772028.",

author = "Simone Koole and {van Stein}, Ruby and {OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group} and Karolina Sikorska and Desmond Barton and Lewis Perrin and Donal Brennan and Oliver Zivanovic and Mosgaard, {Berit Jul} and Anna Fagotti and Pierre-Emmanuel Colombo and Gabe Sonke and Driel, {W J van}",

note = "Funding: The trial is funded by the Dutch Cancer Society (DCS), the Netherlands Organization for Health Research and Development (ZonMW), and the Coverage with Evidence Development (CED) program of the Dutch Ministry of Health. {\textcopyright} IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2020",

month = jun,

day = "1",

doi = "10.1136/ijgc-2020-001231",

language = "English",

volume = "30",

pages = "888--892",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Elsevier Inc.",

number = "6",

}

Koole, S, van Stein, R, OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group, Sikorska, K, Barton, D, Perrin, L, Brennan, D, Zivanovic, O, Mosgaard, BJ, Fagotti, A, Colombo, P-E, Sonke, G & Driel, WJV 2020, 'Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial', International Journal of Gynecological Cancer, vol. 30, no. 6, pp. 888-892. https://doi.org/10.1136/ijgc-2020-001231

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. / Koole, Simone; van Stein, Ruby; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group et al.
In: International Journal of Gynecological Cancer, Vol. 30, No. 6, 01.06.2020, p. 888-892.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer

T2 - OVHIPEC-2, a phase III randomized clinical trial

AU - Koole, Simone

AU - van Stein, Ruby

AU - OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group

AU - Sikorska, Karolina

AU - Barton, Desmond

AU - Perrin, Lewis

AU - Brennan, Donal

AU - Zivanovic, Oliver

AU - Mosgaard, Berit Jul

AU - Fagotti, Anna

AU - Colombo, Pierre-Emmanuel

AU - Sonke, Gabe

AU - Driel, W J van

N1 - Funding: The trial is funded by the Dutch Cancer Society (DCS), the Netherlands Organization for Health Research and Development (ZonMW), and the Coverage with Evidence Development (CED) program of the Dutch Ministry of Health. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.PRIMARY OBJECTIVE: The primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease, or residual disease up to 2.5 mm in maximum dimension.STUDY HYPOTHESIS: We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with primary FIGO stage III epithelial ovarian cancer.TRIAL DESIGN: This international, randomized, open-label, phase III trial will enroll 538 patients with newly diagnosed FIGO stage III epithelial ovarian cancer. Following complete or near-complete (residual disease ≤2.5 mm) primary cytoreduction, patients are randomly allocated (1:1) to receive HIPEC or no HIPEC. All patients will receive six courses of platinum-paclitaxel chemotherapy, and maintenance PARP-inhibitor or bevacizumab according to current guidelines.MAJOR ELIGIBILITY CRITERIA: Patients with FIGO stage III primary epithelial ovarian, fallopian tube, or primary peritoneal cancer are eligible after complete or near-complete primary cytoreductive surgery. Patients with resectable umbilical, spleen, or local bowel lesions may be included. Enlarged extra-abdominal lymph nodes should be negative on FDG-PET or fine-needle aspiration/biopsy.PRIMARY ENDPOINT: The primary endpoint is overall survival.SAMPLE SIZE: To detect a HR of 0.67 in favor of HIPEC, 200 overall survival events are required. With an expected accrual period of 60 months and 12 months additional follow-up, 538 patients need to be randomized.ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The OVHIPEC-2 trial started in January 2020 and primary analyses are anticipated in 2026.TRIAL REGISTRATION: ClinicalTrials.gov:NCT03772028.

AB - BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.PRIMARY OBJECTIVE: The primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease, or residual disease up to 2.5 mm in maximum dimension.STUDY HYPOTHESIS: We hypothesize that the addition of HIPEC to primary cytoreductive surgery improves overall survival in patients with primary FIGO stage III epithelial ovarian cancer.TRIAL DESIGN: This international, randomized, open-label, phase III trial will enroll 538 patients with newly diagnosed FIGO stage III epithelial ovarian cancer. Following complete or near-complete (residual disease ≤2.5 mm) primary cytoreduction, patients are randomly allocated (1:1) to receive HIPEC or no HIPEC. All patients will receive six courses of platinum-paclitaxel chemotherapy, and maintenance PARP-inhibitor or bevacizumab according to current guidelines.MAJOR ELIGIBILITY CRITERIA: Patients with FIGO stage III primary epithelial ovarian, fallopian tube, or primary peritoneal cancer are eligible after complete or near-complete primary cytoreductive surgery. Patients with resectable umbilical, spleen, or local bowel lesions may be included. Enlarged extra-abdominal lymph nodes should be negative on FDG-PET or fine-needle aspiration/biopsy.PRIMARY ENDPOINT: The primary endpoint is overall survival.SAMPLE SIZE: To detect a HR of 0.67 in favor of HIPEC, 200 overall survival events are required. With an expected accrual period of 60 months and 12 months additional follow-up, 538 patients need to be randomized.ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The OVHIPEC-2 trial started in January 2020 and primary analyses are anticipated in 2026.TRIAL REGISTRATION: ClinicalTrials.gov:NCT03772028.

U2 - 10.1136/ijgc-2020-001231

DO - 10.1136/ijgc-2020-001231

M3 - Article

C2 - 32205449

SN - 1048-891X

VL - 30

SP - 888

EP - 892

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 6

ER -

Koole S, van Stein R, OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group, Sikorska K, Barton D, Perrin L et al. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. International Journal of Gynecological Cancer. 2020 Jun 1;30(6):888-892. doi: 10.1136/ijgc-2020-001231

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this